Adverse drug events affecting medication persistence with rivastigmine patch application

PURPOSE: The rivastigmine transdermal patch, the only existing cholinesterase inhibitor available as a transdermal delivery system for treating Alzheimer’s disease, has been reported to inhibit progression of cognitive impairment and impairment in activities of daily living, in addition to reducing...

Descripción completa

Detalles Bibliográficos
Autores principales: Osada, Takashi, Watanabe, Norio, Asano, Naomitsu, Adachi, Yuzo, Yamamura, Keiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055883/
https://www.ncbi.nlm.nih.gov/pubmed/30050286
http://dx.doi.org/10.2147/PPA.S166680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055883/
https://www.ncbi.nlm.nih.gov/pubmed/30050286
http://dx.doi.org/10.2147/PPA.S166680

Ejemplares similares